%0 Journal Article %A Greggs, Willie M. %A Clouser, Christine L. %A Patterson, Steven E. %A Mansky, Louis M. %T Discovery of drugs that possess activity against feline leukemia virus %D 2012 %J Journal of General Virology, %V 93 %N 4 %P 900-905 %@ 1465-2099 %R https://doi.org/10.1099/vir.0.039909-0 %I Microbiology Society, %X Feline leukemia virus (FeLV) is a gammaretrovirus that is a significant cause of neoplastic-related disorders affecting cats worldwide. Treatment options for FeLV are limited, associated with serious side effects, and can be cost-prohibitive. The development of drugs used to treat a related retrovirus, human immunodeficiency virus type 1 (HIV-1), has been rapid, leading to the approval of five drug classes. Although structural differences affect the susceptibility of gammaretroviruses to anti-HIV drugs, the similarities in mechanism of replication suggest that some anti-HIV-1 drugs may also inhibit FeLV. This study demonstrates the anti-FeLV activity of four drugs approved by the US FDA (Food and Drug Administration) at non-toxic concentrations. Of these, tenofovir and raltegravir are anti-HIV-1 drugs, while decitabine and gemcitabine are approved to treat myelodysplastic syndromes and pancreatic cancer, respectively, but also have anti-HIV-1 activity in cell culture. Our results indicate that these drugs may be useful for FeLV treatment and should be investigated for mechanism of action and suitability for veterinary use. %U https://www.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.039909-0